Powered by NAi’s biology-first Bayesian causal AI, BPGbio has generated a deep and diversified discovery pipeline across wide-range disease areas. This pipeline demonstrates NAi’s capability to uncover novel, high-confidence targets and programs far beyond any single pathway or therapeutic area.
Novel Targets Discovered by NAi
High-confidence and Diversified Areas of Target Biology for Drug Discovery
The 75 targets discovered by the NAi platform span multiple biological mechanisms and disease pathways. Whether it’s mitochondrial metabolism, protein homeostasis, cytoskeletal regulation, signal transduction, or immune modulation, NAi’s causal modeling finds high-value biology across distinct therapeutic domains.
75 | 6 | 5 | 8 |
Target Validation Programs | Drug Discovery Programs | IND Approved | Clinical Development |
Contact BD@BPGbio.com to discuss licensing and partnership opportunities.
BPGbio Robust Clinical Pipeline
Indication / Asset | Known Activity | Discovery | Hit to Lead | Lead | IND | Phase 1 | Phase 2 | Phase 3 | ||
Clinical Programs | ||||||||||
Glioblastoma (GBM)BPM31510-IV | Radiation Sensitizer | |||||||||
Pancreatic CancerBPM31510-IV | Chemotherapy Sensitizer | |||||||||
Primary CoQ10 DeficiencyBPM31510-IV | Direct Replacement | a phase 3 trial is being planned | ||||||||
Squamous Cell Carcinoma BPM31510-T | Wound Healing | |||||||||
Epidermolysis BullosaBPM31510-T | Wound Healing | |||||||||
SarcopeniaBPM31510-Oral | Mitochondrial Respiration | |||||||||
Solid and Liquid Tumors BRG399 | Tubulin Polymerization | |||||||||
Secondary CVD Prevention BRG399 | Neutrophil Inflammation | |||||||||
BPM31510, has received FDA Rare Pediatric Disease Designation for Primary Coenzyme Q10 Deficiency (PCQD) and Epidermolysis Bullosa (EB) respectively. The company is planning a potential pivotal trial in Primary CoQ10 Deficiency. Upon Approval, both designations provide BPGbio eligibility for a Priority Review Voucher (PRV). | ||||||||||
Indication | Target Class | Discovery | Hit to Lead | Lead | IND | Phase 1 | Phase 2 | Phase 3 | ||
Drug Discovery Programs | ||||||||||
Huntington Disease BPG812 | Ubiquitin Proteosomal | |||||||||
Oncology BPG1438 | Targeted Protein Degradation | |||||||||
Parkinson’s Disease BRGP0811 | Oxidoreductase Target | |||||||||
Oncology Hit Molecules | DNA RNA Helicases | |||||||||
Oncology Hit Molecules | Ubiquitin Proteosomal | |||||||||
Angiogenesis BRG0001 | ||||||||||
Novel Target Biology Discovery by the NAi Platform
Indication | Pathway / Biology Area | # of Targets |
Parkinson’s Disease (19 targets) | Cytoskeleton, adhesion, migration | 8 |
ECM & stromal biology | 2 | |
Stress & metabolic signaling | 4 | |
DNA damage & gene regulation | 2 | |
RNA processing & gene regulation | 3 | |
Alzheimer’s Disease (8 targets) | ER protein folding & UPR | 3 |
Mitochondrial ATP synthesis (OXPHOS) | 2 | |
Cytoskeleton & membrane trafficking | 3 | |
Huntington’s Disease | Autophagy-Proteostasis Cross-Talk | 1 |
Autism (11 targets) | Antigen processing & immunity | 4 |
Apoptosis | 1 | |
ER proteostasis / UPR | 2 | |
RNA metabolism & translation control | 2 | |
GPCR signaling | 1 | |
Mitochondrial ion/metabolic regulation | 1 | |
Oncology (28 Targets) | Protein folding, ER stress & proteostasis | 8 |
RNA processing & translational control | 7 | |
Mitochondrial biology & metabolism | 3 | |
Cytoskeleton & intracellular transport | 4 | |
Signal transduction (phosphatases) | 2 | |
ECM / developmental regulation & chomatin architecture | 4 | |
Diabetes (4 targets) | Energy metabolism: glycolysis & TCA | 3 |
Protein folding / molecular chaperones | 1 | |
Obesity (4 targets) | Extracellular Matrix / Structural Proteins | 2 |
Metabolism / Lipid Biosynthesis | 1 | |
Ubiquitin-Proteasome System / Protein Degradation | 1 | |
BPGbio First-In-Class Diagnostic Pipeline
